Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: A case report.
Ewing sarcoma
immunotherapy
nivolumab
Journal
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
ISSN: 1477-092X
Titre abrégé: J Oncol Pharm Pract
Pays: England
ID NLM: 9511372
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
pubmed:
20
10
2020
medline:
6
7
2021
entrez:
19
10
2020
Statut:
ppublish
Résumé
Although, immune check-point inhibitors changed the course of many cancers, the outcomes in sarcomas were rather disappointing with less than 10% response rates. Ewing sarcoma is a poorly differentiated and aggressive tumor mostly seen in the children and adolescents. It's a distinct type of sarcoma with prominent chemosensitivity in the early stages. However, the relapsing disease has a poor prognosis with limited treatment options. Herein, we represent a case of relapsed Ewing sarcoma treated with multiple lines of chemotherapy. We think that chemotherapy plus immunotherapy can be an option for Ewing sarcoma patients treated with multiple lines of chemotherapy.
Identifiants
pubmed: 33070764
doi: 10.1177/1078155220965677
doi:
Substances chimiques
Paclitaxel
P88XT4IS4D
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM